ASX healthcare stock Vitrafy Life Sciences Ltd (ASX: VFY) has been one of the hottest shares in 2026.
The company has designed and developed an innovative solution to advance cryopreservation, including smart devices, a quality management software platform, and smart packaging solutions.
Commercial success has led to significant share price gains of almost 150% in 2026 alone.
A new report from Bell Potter suggests this is likely to continue, with the broker significantly increasing its 12-month price target.Â
$30 million capital raise
Vitrafy recently raised $30 million from institutional investors at $2.60 per share.
Following this, the company announced a Share Purchase Plan (SPP).
The company said the SPP intends to raise up to $2 million.Â
The SPP provides Eligible Shareholders with the opportunity to acquire new fully paid ordinary shares in the Company (“New Shares”) at the same price as the institutional placement announced to the ASX on Friday, 12 June 2026, which raised A$30 million.
Each Eligible Shareholder may apply for up to A$30,000 worth of New Shares at the offer price of A$2.60 per New Share, irrespective of the size of their holding in Vitrafy, without incurring brokerage or transaction costs.
What is Bell Potter’s view?
Following this announcement, the team at Bell Potter provided updated guidance on this ASX healthcare stock.
The broker largely appears constructive/bullish on the capital raise, viewing it as growth funding rather than a rescue financing.
According to the report, commercial traction is improving, with positive developments in military blood studies, animal reproduction partnerships, and growing interest from the U.S. civilian blood market.
The $32 million total raise (A$30m placement + A$2m SPP) provides enough capital to manufacture approximately 100 units and accelerate commercial deployment.
Bell Potter estimates those units could generate around A$12 million of annual managed-service revenue, plus recurring consumable sales.
Target price increase for ASX healthcare stock
This ASX healthcare stock closed trading yesterday at $3.19 per share.
The team at Bell Potter have now upgraded their 12-month price target to $5.15 (previously $3.00).Â
It has retained its speculative buy recommendation.
This indicates an upside potential of 61% from current levels.
The capital raising and developments in the Red Blood Cell market have instigated a revision to our estimates, particularly from FY28 on the revenue line, where we see 175 total units being installed by FY30 which could generate $80m in annual revenue.
We still anticipate VFY reaching breakeven by FY30.
The post This ASX healthcare stock just got a big upgrade following capital raise appeared first on The Motley Fool Australia.
Should you invest $1,000 in Vitrafy Life Sciences right now?
Before you buy Vitrafy Life Sciences shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Vitrafy Life Sciences wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 16 June 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Is this exciting healthcare stock a buy, hold or sell after rocketing 16% yesterday?
- What is Morgan’s updated view on this red hot ASX healthcare stock?
Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.